Trial Profile
Clinical Trials Insight: 700007646
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 11 Nov 2005
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Oblimersen (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Nov 2005 New trial record.